stockrow
Friday 6 November 2026
Export VXRT’s income statement to Excel — free account
VAXART, INC.
VXRT Healthcare Biotechnology
VAXART, INC.’s revenue for fiscal 2025 (year ended December 2025) was $237.3 million, up 726.7% from fiscal 2024.
- Revenue
- −85.3%
- EPS
- −75.0%
- Free cash flow
- −57.2%
Quarter to September 2026, against a year earlier
0.37
0.03
−7.50%
Follow VXRT
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 From the 10-Q filed 5 Nov | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
5.83 | 4.07 | 3.81 | 3.46 |
P/S ratio |
0.34 | 0.57 | 0.61 | 0.60 | |
P/FCF ratio |
10.64 | 9.92 | 4.42 | 3.42 | |
P/Operating CF |
2.63 | (71.47) | 53.18 | 76.35 | |
P/B ratio |
0.92 | 1.56 | 1.79 | 1.65 | |
Price to Tangible BV |
1.00 | 1.69 | 1.96 | 1.84 | |
EV/Sales |
0.08 | 0.34 | 0.35 | 0.25 | |
EV/EBITDA |
0.68 | 1.91 | 1.87 | 0.99 | |
EV/Operating CF |
2.33 | 5.70 | 2.50 | 1.37 | |
EV/FCF |
2.37 | 5.87 | 2.54 | 1.41 | |
Quick Ratio |
1.33 | 1.54 | 1.52 | 1.30 | |
Current Ratio |
1.57 | 1.71 | 1.60 | 1.71 | |
Net Debt/EBITDA |
(1.12) | (9.77) | 5.11 | 0.00 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
1.35 | 1.51 | 1.48 | 1.02 | |
Operating CF/Net income |
0.56 | (0.40) | (0.21) | (0.08) | |
Capex/Depreciation |
0.00 | (0.42) | (0.04) | 0.00 | |
Interest Coverage |
101.51 | 10.24 | (24.48) | — | |
Research and Development Expense of Revenue |
43.31% | 74.98% | 124.16% | 214.96% | |
Selling, General and Administrative Expense of Revenue |
3.52% | 11.83% | 24.29% | 47.78% | |
Intangible Assets out of Total Assets |
0.04 | 0.04 | 0.04 | 0.05 | |
Share Based Compensation of Revenue |
1.65% | 3.78% | 4.75% | 11.22% | |
Graham Net Nets |
0.47 | 0.31 | 0.23 | 0.41 | |
Graham Number |
0.72 | 1.15 | 1.11 | 0.89 | |
Earnings Yield |
17.14% | 24.59% | 26.23% | 28.89% | |
Free Cash Flow Yield |
9.40% | 10.08% | 22.61% | 29.23% | |
Revenue per Share |
0.45 | 0.16 | 0.11 | 0.04 | |
Operating CF per Share |
0.13 | (0.01) | 0.01 | 0.01 | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.13 | (0.01) | 0.01 | 0.00 | |
Cash per Share |
0.28 | 0.25 | 0.26 | 0.27 | |
Shareholders Equity per Share |
0.38 | 0.39 | 0.34 | 0.27 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.38 | 0.39 | 0.34 | 0.27 | |
Free Cash Flow |
30.66 | (2.50) | 2.75 | 1.06 | |
Working Capital |
49.37 | 54.86 | 43.58 | 52.50 | |
Capital Expenditures |
0.00 | (0.44) | (0.02) | (0.37) | |
Net Current Asset Value |
37.84 | 45.77 | 33.88 | 44.54 | |
EV/EBIT |
0.99 | 2.28 | 2.14 | 1.49 | |
Capex to Sales |
0.00 | 0.01 | 0.00 | 0.03 | |
Price to Operating Income |
4.46 | 3.84 | 3.73 | 3.63 | |
| Other line items | |||||
Average Receivables |
31.66 | 36.85 | 44.03 | 58.22 | |
Average Payables |
14.23 | 20.40 | 13.79 | 41.43 | |
Average Assets |
176.23 | 169.31 | 164.64 | 178.58 | |
Average Common Equity |
73.36 | 69.87 | 57.62 | 46.52 |
Columns are period end dates · fundamentals updated 5 Nov 2026